Factors associated with immunotherapy use among newly diagnosed cancer patients

Ya Chen Tina Shih, Linda S. Elting, Michael Halpern

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

CONTEXT: Immunotherapy represents a newer modality for cancer treatment with substantial health benefits. However, the high costs of immunotherapy may create access barriers. OBJECTIVE: To examine factors associated with the utilization of immunotherapy among newly diagnosed cancer patients. DESIGN AND SETTING: Analysis of a large national cancer registry data, the National Cancer Data Base, that represents approximately 75% of newly diagnosed cancer patients in the US. PATIENTS: Patient diagnosed with non-Hodgkin lymphoma (NHL), metastatic breast cancer (MBC), or metastatic colorectal cancer (MCRC). MAIN OUTCOME MEASURES: Factors associated with utilization of immunotherapy in NHL, MBC, or MCRC. RESULTS: The study included 207,581 and 42,804 patients diagnosed with NHL and MBC between 1998 and 2004, respectively (based on approval of rituximab in 1997 and trastuzumab in 1998); and 16,027 patients diagnosed with MCRC in 2004 (based on approval of cetuximab and bevacizumab in 2004). Immunotherapy use varied significantly by age, race, insurance status, year of diagnosis, and type of treatment facilities, with largest effects observed in years of diagnosis, followed by insurance status. Among young cancer patients, we found that compared with uninsured patients, the odds of receiving immunotherapy were 1.61, and 2.13 for privately insured MBC, and MCRC patients, respectively, and were in the range of 1.13 to 19.23 for privately insured NHL patients. For elderly NHL patients, those with secondary insurance in addition to Medicare were 1.26 to 8.24 times more likely to receive immunotherapy than those with Medicare alone. CONCLUSIONS: The disparities observed in this study suggest that additional efforts are required to ensure that all cancer patients receive timely and appropriate treatment.

Original languageEnglish (US)
Pages (from-to)948-958
Number of pages11
JournalMedical Care
Volume47
Issue number9
DOIs
StatePublished - Sep 2009
Externally publishedYes

Fingerprint

Immunotherapy
Non-Hodgkin's Lymphoma
Neoplasms
Colorectal Neoplasms
Breast Neoplasms
Insurance Coverage
Medicare
Insurance Benefits
Insurance
Registries
Therapeutics
Outcome Assessment (Health Care)
Databases
Costs and Cost Analysis

Keywords

  • Cancer
  • Immunotherapy
  • Insurance endogeneity
  • Technology diffusion

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Factors associated with immunotherapy use among newly diagnosed cancer patients. / Shih, Ya Chen Tina; Elting, Linda S.; Halpern, Michael.

In: Medical Care, Vol. 47, No. 9, 09.2009, p. 948-958.

Research output: Contribution to journalArticle

Shih, Ya Chen Tina ; Elting, Linda S. ; Halpern, Michael. / Factors associated with immunotherapy use among newly diagnosed cancer patients. In: Medical Care. 2009 ; Vol. 47, No. 9. pp. 948-958.
@article{e97b9980f7ab4978b4c12000d04ffb82,
title = "Factors associated with immunotherapy use among newly diagnosed cancer patients",
abstract = "CONTEXT: Immunotherapy represents a newer modality for cancer treatment with substantial health benefits. However, the high costs of immunotherapy may create access barriers. OBJECTIVE: To examine factors associated with the utilization of immunotherapy among newly diagnosed cancer patients. DESIGN AND SETTING: Analysis of a large national cancer registry data, the National Cancer Data Base, that represents approximately 75{\%} of newly diagnosed cancer patients in the US. PATIENTS: Patient diagnosed with non-Hodgkin lymphoma (NHL), metastatic breast cancer (MBC), or metastatic colorectal cancer (MCRC). MAIN OUTCOME MEASURES: Factors associated with utilization of immunotherapy in NHL, MBC, or MCRC. RESULTS: The study included 207,581 and 42,804 patients diagnosed with NHL and MBC between 1998 and 2004, respectively (based on approval of rituximab in 1997 and trastuzumab in 1998); and 16,027 patients diagnosed with MCRC in 2004 (based on approval of cetuximab and bevacizumab in 2004). Immunotherapy use varied significantly by age, race, insurance status, year of diagnosis, and type of treatment facilities, with largest effects observed in years of diagnosis, followed by insurance status. Among young cancer patients, we found that compared with uninsured patients, the odds of receiving immunotherapy were 1.61, and 2.13 for privately insured MBC, and MCRC patients, respectively, and were in the range of 1.13 to 19.23 for privately insured NHL patients. For elderly NHL patients, those with secondary insurance in addition to Medicare were 1.26 to 8.24 times more likely to receive immunotherapy than those with Medicare alone. CONCLUSIONS: The disparities observed in this study suggest that additional efforts are required to ensure that all cancer patients receive timely and appropriate treatment.",
keywords = "Cancer, Immunotherapy, Insurance endogeneity, Technology diffusion",
author = "Shih, {Ya Chen Tina} and Elting, {Linda S.} and Michael Halpern",
year = "2009",
month = "9",
doi = "10.1097/MLR.0b013e31819a5b2b",
language = "English (US)",
volume = "47",
pages = "948--958",
journal = "Medical Care",
issn = "0025-7079",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Factors associated with immunotherapy use among newly diagnosed cancer patients

AU - Shih, Ya Chen Tina

AU - Elting, Linda S.

AU - Halpern, Michael

PY - 2009/9

Y1 - 2009/9

N2 - CONTEXT: Immunotherapy represents a newer modality for cancer treatment with substantial health benefits. However, the high costs of immunotherapy may create access barriers. OBJECTIVE: To examine factors associated with the utilization of immunotherapy among newly diagnosed cancer patients. DESIGN AND SETTING: Analysis of a large national cancer registry data, the National Cancer Data Base, that represents approximately 75% of newly diagnosed cancer patients in the US. PATIENTS: Patient diagnosed with non-Hodgkin lymphoma (NHL), metastatic breast cancer (MBC), or metastatic colorectal cancer (MCRC). MAIN OUTCOME MEASURES: Factors associated with utilization of immunotherapy in NHL, MBC, or MCRC. RESULTS: The study included 207,581 and 42,804 patients diagnosed with NHL and MBC between 1998 and 2004, respectively (based on approval of rituximab in 1997 and trastuzumab in 1998); and 16,027 patients diagnosed with MCRC in 2004 (based on approval of cetuximab and bevacizumab in 2004). Immunotherapy use varied significantly by age, race, insurance status, year of diagnosis, and type of treatment facilities, with largest effects observed in years of diagnosis, followed by insurance status. Among young cancer patients, we found that compared with uninsured patients, the odds of receiving immunotherapy were 1.61, and 2.13 for privately insured MBC, and MCRC patients, respectively, and were in the range of 1.13 to 19.23 for privately insured NHL patients. For elderly NHL patients, those with secondary insurance in addition to Medicare were 1.26 to 8.24 times more likely to receive immunotherapy than those with Medicare alone. CONCLUSIONS: The disparities observed in this study suggest that additional efforts are required to ensure that all cancer patients receive timely and appropriate treatment.

AB - CONTEXT: Immunotherapy represents a newer modality for cancer treatment with substantial health benefits. However, the high costs of immunotherapy may create access barriers. OBJECTIVE: To examine factors associated with the utilization of immunotherapy among newly diagnosed cancer patients. DESIGN AND SETTING: Analysis of a large national cancer registry data, the National Cancer Data Base, that represents approximately 75% of newly diagnosed cancer patients in the US. PATIENTS: Patient diagnosed with non-Hodgkin lymphoma (NHL), metastatic breast cancer (MBC), or metastatic colorectal cancer (MCRC). MAIN OUTCOME MEASURES: Factors associated with utilization of immunotherapy in NHL, MBC, or MCRC. RESULTS: The study included 207,581 and 42,804 patients diagnosed with NHL and MBC between 1998 and 2004, respectively (based on approval of rituximab in 1997 and trastuzumab in 1998); and 16,027 patients diagnosed with MCRC in 2004 (based on approval of cetuximab and bevacizumab in 2004). Immunotherapy use varied significantly by age, race, insurance status, year of diagnosis, and type of treatment facilities, with largest effects observed in years of diagnosis, followed by insurance status. Among young cancer patients, we found that compared with uninsured patients, the odds of receiving immunotherapy were 1.61, and 2.13 for privately insured MBC, and MCRC patients, respectively, and were in the range of 1.13 to 19.23 for privately insured NHL patients. For elderly NHL patients, those with secondary insurance in addition to Medicare were 1.26 to 8.24 times more likely to receive immunotherapy than those with Medicare alone. CONCLUSIONS: The disparities observed in this study suggest that additional efforts are required to ensure that all cancer patients receive timely and appropriate treatment.

KW - Cancer

KW - Immunotherapy

KW - Insurance endogeneity

KW - Technology diffusion

UR - http://www.scopus.com/inward/record.url?scp=69449103702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69449103702&partnerID=8YFLogxK

U2 - 10.1097/MLR.0b013e31819a5b2b

DO - 10.1097/MLR.0b013e31819a5b2b

M3 - Article

C2 - 19704352

AN - SCOPUS:69449103702

VL - 47

SP - 948

EP - 958

JO - Medical Care

JF - Medical Care

SN - 0025-7079

IS - 9

ER -